Close Menu
Truth Republican
  • Home
  • News
  • Politics
  • Business
  • Guns & Gear
  • Healthy Tips
  • Prepping & Survival
  • Videos
Facebook X (Twitter) Instagram
Truth Republican
  • Home
  • News
  • Politics
  • Business
  • Guns & Gear
  • Healthy Tips
  • Prepping & Survival
  • Videos
Newsletter
Truth Republican
You are at:Home»Healthy Tips»New breast cancer drug wins FDA approval after slashing progression risk by nearly 40%
Healthy Tips

New breast cancer drug wins FDA approval after slashing progression risk by nearly 40%

Buddy DoyleBy Buddy DoyleOctober 1, 2025No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp
New breast cancer drug wins FDA approval after slashing progression risk by nearly 40%
Share
Facebook Twitter LinkedIn Pinterest Email

NEWYou can now listen to Fox News articles!

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer.

Drugmaker Eli Lilly announced on Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to treat adults with specific types of the disease.

Those types include estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer.

WEIGHT LOSS COULD BE JUST A PILL AWAY, STUDY OF NEW MEDICATION SUGGESTS

The once-daily pill is also meant for those who saw disease progression after at least one line of endocrine (hormone) therapy, according to a press release.

In the phase 3 EMBER-3 trial, Inluriyo reportedly reduced the risk of cancer progression or death by 38% compared to endocrine therapy.

Patients with ESR1-mutated metastatic breast cancer saw a “significant” improvement in progression-free survival with Inluriyo, compared to other hormone treatments like fulvestrant or exemestane, with a median survival of 5.5 months versus 3.8 months.

Function and side effects

Some cancers develop mutations that can cause estrogen receptors to “become overactive and drive cancer growth,” Eli Lilly noted.

Inluriyo works to bind, block and facilitate the “degradation of these receptors,” which helps to slow the disease progression.

CANCER VACCINE SHOWS PROMISE IN PREVENTING RECURRENCE OF PANCREATIC, COLORECTAL TUMORS

“This represents an important advancement for patients with ESR1-mutated MBC, a mutation found in nearly half of patients who have taken hormone therapies, often contributing to treatment resistance,” study lead Komal Jhaveri, M.D., section head of endocrine therapy research and clinical director of early drug development at Memorial Sloan Kettering Cancer Center, commented in a press release statement.

“With its demonstrated efficacy, tolerability profile and oral administration, this therapy provides a meaningful alternative treatment option for this patient population.”

Woman getting ultrasound

Inluriyo comes with a warning that it may be dangerous for an unborn baby, which means women who are pregnant or could become pregnant should talk to their doctor before taking it.

During the phase 3 trial, common side effects were “low grade” but included lab abnormalities, musculoskeletal pain, fatigue, diarrhea, nausea, constipation, abdominal pain, an increase in cholesterol and triglycerides, and a reduction in hemoglobin, calcium, platelets, white blood cells and certain enzymes mostly found in the liver, per the FDA.

“It’s critical to ensure patients receive informed, individualized guidance.”

Around 4.6% of patients discontinued treatment due to these adverse events, while 2.4% reduced their doses and 10% had dose interruptions.

‘Hopeful but vigilant’

Jacob Van Naarden, executive vice president and president of Lilly Oncology in Indianapolis, commented that this therapy “reflects our commitment to developing treatments that improve outcomes for people with breast cancer and represents an important step toward advancing innovative, all-oral treatment approaches.”

“This therapy has the potential to make the treatment journey more manageable for those living with breast cancer.”

Eli Lilly shared that Inluriyo will continue to be studied in the ongoing phase 3 EMBER-4 trial for patients with ER+, HER2– early breast cancer at an increased recurrence risk. This trial will enroll about 8,000 patients globally.

Inluriyo is expected to be available in the U.S. in “the coming weeks,” according to the company.

Breast cancer patient pills

Fox News medical contributor Dr. Nicole Saphier, radiologist and director of breast imaging at Memorial Sloan Kettering Cancer Center in New York, reacted to the drug approval in an interview with Fox News Digital.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

“In approving this new medication, the FDA has granted patients who develop resistance to first-line therapies with a new, evidence-based option — one that showed a 38% reduction in risk of progression or death in the EMBER-3 trial,” she said.

“Just this morning, I saw a woman whose cancer persists because of this exact ESR1 mutation, and breakthroughs like this are changing the landscape — delivering more selective treatments and giving people who once felt hopeless, hope.”

For more Health articles, visit www.foxnews.com/health

Saphier added that it’s “critical to remain vigilant” about potential safety issues with this treatment, including fatal cardiovascular events — “and to ensure that patients receive informed, individualized guidance.”

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous Article13 times Democrats voted for a short-term continuing resolution under Biden
Next Article Shutdown halts $18B in federal funds for two of NYC’s biggest transit projects

Related Articles

Deadly mosquito-borne virus sparks CDC travel alert — could it reach the US?

Deadly mosquito-borne virus sparks CDC travel alert — could it reach the US?

October 1, 2025
World’s oldest woman lived to 117 thanks to 6 healthy aging secrets

World’s oldest woman lived to 117 thanks to 6 healthy aging secrets

October 1, 2025
Doctors say eating specific type of food may offset lung damage from air pollution

Doctors say eating specific type of food may offset lung damage from air pollution

September 30, 2025
New type of diabetes requires its own unique treatment, researchers say

New type of diabetes requires its own unique treatment, researchers say

September 30, 2025
Your next workout could get a boost with a strange kitchen combo that’s gone viral

Your next workout could get a boost with a strange kitchen combo that’s gone viral

September 29, 2025
Weight-loss drugs now linked to cancer protection in women, major new study reveals

Weight-loss drugs now linked to cancer protection in women, major new study reveals

September 29, 2025
7 common fitness mistakes older adults make and how to avoid them for better workouts

7 common fitness mistakes older adults make and how to avoid them for better workouts

September 27, 2025
Common vitamin shown to slash skin cancer risk in some groups, study suggests

Common vitamin shown to slash skin cancer risk in some groups, study suggests

September 26, 2025
Autism symptoms in adults and new virus surge, plus GLP-1 benefits

Autism symptoms in adults and new virus surge, plus GLP-1 benefits

September 26, 2025
Don't Miss
Amazon unveils ‘price-conscious’ grocery brand featuring more than 1,000 items nationwide

Amazon unveils ‘price-conscious’ grocery brand featuring more than 1,000 items nationwide

Deadly mosquito-borne virus sparks CDC travel alert — could it reach the US?

Deadly mosquito-borne virus sparks CDC travel alert — could it reach the US?

First bipartisan shutdown negotiations surface on Capitol Hill after funding bill blocked again

First bipartisan shutdown negotiations surface on Capitol Hill after funding bill blocked again

Fox News Politics Newsletter: Trump’s peace plan could stop the Gaza war — or topple Netanyahu

Fox News Politics Newsletter: Trump’s peace plan could stop the Gaza war — or topple Netanyahu

Latest News
Secretary of War Says U.S. “Must Prepare For War”

Secretary of War Says U.S. “Must Prepare For War”

October 1, 2025
Outrage Grows After Murder Of 22-Year-Old By Man With 40 Charges

Outrage Grows After Murder Of 22-Year-Old By Man With 40 Charges

October 1, 2025
Beef prices hit record highs as nationwide cattle inventory drops to lowest level in 70 years

Beef prices hit record highs as nationwide cattle inventory drops to lowest level in 70 years

October 1, 2025
Kamala Harris book reveals marital rift with Doug Emhoff during campaign

Kamala Harris book reveals marital rift with Doug Emhoff during campaign

October 1, 2025
Carnival ride passengers left dangling in carriage after malfunction at high school event: video

Carnival ride passengers left dangling in carriage after malfunction at high school event: video

October 1, 2025
Copyright © 2025. Truth Republican. All rights reserved.
  • Privacy Policy
  • Terms of use
  • Contact

Type above and press Enter to search. Press Esc to cancel.